Blackfin Bio is a spinout company from the University of Sheffield, leveraging the university’s research and intellectual property to pursue its innovative endeavours in biotechnology. Our pioneering work on SPG47 provides us with a platform to research treatments for other debilitating neurological diseases.

We are one of only a handful of biotech companies researching and developing treatments for rare subsets of HSP.

We plan to complement our flagship program with additional initiatives currently under discussion, including those related to dopamine deficiency diseases like Parkinson’s disease, which affects over 10 million people worldwide. We are actively engaged in exploring these opportunities further.

Invest in Blackfin Bio and you will be at the forefront of groundbreaking research and treatments for SPG47 and other neurological diseases.

The U.S. Food and Drug Administration (FDA) grants special incentives including Priority Review Vouchers (PRVs) used in developing treatments for rare and neglected paediatric diseases such as SPG47.

These vouchers provide a game-changing advantage by expediting the FDA review process, making them extremely valuable to pharmaceutical companies looking to fast-track product development.

PRVs are transferable which means we can sell these vouchers for substantial sums, adding non-dilutive funding that would significantly impact our growth strategy and ensure a robust return on investment for our stakeholders.

As we refine and update our investor page, we aim to provide a comprehensive and compelling overview of our position in the biotech landscape, emphasising our potential for commercial success and the broader scope of our research efforts.

Discover the potential of investing in future neurological breakthroughs with Blackfin Bio by reading our non-confidential investor deck here.